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2 
Abstract 
 
Epithelial organ remodeling is a major contributing factor to worldwide death and disease, 
costing healthcare systems billions of dollars every year. Despite this, most fundamental 
epithelial organ research fails to produce new therapies and mortality rates for epithelial organ 
diseases remain unacceptably high. In large part, this failure in translating basic epithelial 
research into clinical therapy is due to a lack of relevance in existing preclinical models. To 
correct this, new models are required that improve preclinical target identification, 
pharmacological lead validation, and compound optimization. In this review, we discuss the 
relevance of human stem cell-derived, three-dimensional organoid models for addressing each 
of these challenges. We highlight the advantages of stem cell-derived organoid models over 
existing culture systems, discuss recent advances in epithelial tissue-specific organoids, and 
present a paradigm for using organoid models in human translational medicine. 
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Introduction 
Irreversible epithelial organ remodelling is a major contributing factor to worldwide 
death and disease, costing healthcare systems billions of dollars every year.  Diseases of 
epithelial remodelling include lung and gastrointestinal cancers as well as chronic diseases such 
as chronic obstructive pulmonary disease (COPD), liver cirrhosis and inflammatory bowel 
disease.  Sadly, most epithelial organ research fails to produce new therapies for these diseases 
and mortality rates remain unacceptably high 1.  This is because significant barriers exist at all 
levels for translating fundamental biomedical research into clinically relevant therapies 2. 
Translating biomedical research into therapy typically involves preclinical target and 
assay identification, high-throughput in vitro compound screening, animal-based safety and 
pharmacodynamic testing, and eventual human clinical trials.  Unfortunately, reliance on this 
pathway fails to capture many aspects necessary for taking discovery science into clinical 
practice 3.  This is exemplified by the fact that 90% of compounds identified during high-
throughput screening fail to progress beyond Phase 1 clinical trials.  Of those compounds that 
do progress to clinical trials a further 90% will fail to become new drugs 4.  The cost 
implications of these failures are potentially enormous, with the development of each new drug 
recently estimated to cost as much as $1.8  billion 4.  The health implications of compounds 
failing in human clinical trials are also significant.  An illustration of this point was the severe 
reaction caused by the agonist monoclonal antibody TGN1412 in a Phase I clinical trial5.  Here, 
patients experienced a systemic cytokine storm and multi-organ failure despite the compound 
having exhibited a good safety profile in earlier animal models 6.   
These exceptional costs and the relative paucity of new drug approvals highlight the 
fact that new approaches are needed for epithelial translational medicine.  Key challenges 
include identifying which fundamental discoveries are most relevant as potential therapies 
(identifying appropriate targets), addressing the observation that in vitro and animal models 
often do not reflect human physiology (adequately validating lead compounds), and accounting 
for human population variability during preclinical testing (improving lead optimization).  In 
this review, we discuss the relevance of human stem cell-derived epithelial organoids as a new 
tool to address these points.  We highlight advantages of stem cell-derived epithelial organoid 
models relative to other culture systems, discuss recent advances in tissue-specific organoids, 
and present a paradigm for using human stem cell-derived organoid models to deliver a high-
throughput and high content epithelial translational medicine platform.  
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Figure 1.  The benefits of stem cell-derived organoid models for epithelial translational 
medicine.  (A) In vivo, epithelial cells inhabit complex organ microenvironments that are 
composed of epithelial cells, stromal cells, and the surrounding extracellular matrix. (B) Two 
dimensional culture models do not resemble normal in vivo tissues.  (C) Stem cell-derived 
organoid models recapitulate in vivo cellular interactions, multipotent differentiation, and in 
vivo tissue architecture. 
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Advantages of stem cell-derived organoid models  
 
In the simplest terms, organoid models include three dimensional (3D) cell culture 
systems that closely resemble the in vivo organ or tissue from which they were derived.  These 
3D systems reproduce the complex spatial morphology of a differentiated epithelium to allow 
biologically relevant cell-cell and cell-matrix interactions.  Ideally, the physical, cellular, and 
molecular characteristics of 3D organoid models mean that they share similar physiological 
responses with in vivo differentiated epithelia.  This is in contrast to traditional two dimensional 
(2D) cell culture models that often bear little physical, molecular, or physiological similarity to 
their tissue of origin.   
 
Although the earliest 3D epithelial organoid models were first described over 40 years 
ago their utility in translational medicine has until recently remained limited 7.  This was 
because early organoid models required large numbers of starting cells, were not amenable to 
high-throughput screening, and often exhibited limited in vitro viability 8.  These drawbacks 
have now been largely eliminated as advances in multipotent stem and progenitor cell isolation 
have allowed researchers to develop highly reproducible, long-lived organoids from single cells 
9-11
.  Stem and progenitor cells maintain robust regenerative capacity, multipotent 
differentiation potential, and exhibit long-term residence within their tissue of origin.  
Properties of 3D epithelial organoids that distinguish them from 2D culture models include the 
presence of multipotent cellular differentiation, biologically relevant cellular signaling, and a 
complex intercellular communication and organization network (Figure 1).     
 
Multipotent cellular differentiation 
 
 By definition, epithelial organoids comprise multiple differentiated cell types which are 
found in the relevant organ in vivo. For example, all cell types of the intestinal epithelium are 
represented in the Matrigel-based model described by Sato and colleagues 9. This is in stark 
contrast to protocols which are reliant upon 2D primary cultures or cell lines which are often 
composed entirely of undifferentiated cell types and as such bear little resemblance to the 
intended parent organ. Sato and colleagues also found that the inclusion of differentiated 
epithelial Paneth cells increased organoid forming efficiency from approximately 7% to over 
75% of Lgr5(+) stem cells 12. This supports the hypothesis that multipotent cellular 
differentiation is itself required for normal organoid formation. 
 
 Separately, epithelial organoid models have the capacity to integrate additional cells that 
improve their growth and differentiation 13. Airway epithelial studies have shown that the 
inclusion of niche-specific supporting cell populations enhances organoid growth and 
differentiation10. Separate work has also shown that including specific mesenchymal cell 
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populations can further improve airway epithelial organoid formation10, 14.  Impressively, 
organoid branching reminiscent of developmental airway morphogenesis has been reported 
following co-culture of lung epithelial organoids with human endothelial cells 15. These results 
suggest that both epithelial and non-epithelial cells provide specific factors and matrix 
molecules that are relevant for organoid growth and differentiation. 
 
Biologically relevant signaling 
 
 A recurring observation in organoid models is that the signaling pathways governing 
organoid formation are identical to those utilized during in vivo organ development and 
homeostasis.  Specifically, canonical Wnt/β-Catenin and Notch pathway signaling are known to 
be of central importance both in vitro and in vivo. This is perhaps unsurprising given that these 
pathways are widely involved in many important stages of endodermal organ development 16. 
For example, Notch signaling in liver development regulates fate decisions made by biliary 
epithelial cells while Wnt signaling initiates hepatic specification 16. In adult tissues, canonical 
Wnt and Notch signaling maintains proliferation of many epithelial cell types and their 
perturbation is strongly associated with the onset of epithelial disease 17.  In vivo activation of 
the Wnt-β-catenin pathway in human lung and intestinal epithelia causes cellular 
hyperproliferation 18, 19, suppresses ciliated cell differentiation 19, and can promote early lung 
and intestinal neoplasias 17, 20.  Separately, signaling via the Notch ligands Dll1 and Dll4 
increases intestinal crypt-associated stem cell abundance 21 and determines in vivo ciliated 
versus muco-secretory cell differentiation 22.   
 
Intercellular communication and organization networks 
 
 The complex intercellular communication and organization networks present in most 
tissues are difficult to study in 2D monolayer cultures.   This is because in vivo, cells exist 
within a complex network that provides important signaling and biomechanical components. It 
is now known that cellular communication through  force generation is important for normal 
cellular growth and differentiation.  Specifically, work by Bissell and colleagues demonstrated 
that the phenotype of mammary epithelial cells varies in response to the overall stiffness and 
composition of the extracellular matrix (ECM). Cells cultured in elastic substrata comparable to 
the in vivo mammary tissue environment maintain an in vivo-like morphology whereas stiffer 
substrates induce uncontrolled cell spreading and proliferation 23. Further, Gjorevski and 
Nelson found that epithelial tissues cultured in three dimensions experience patterns of 
mechanical stress more comparable to those of in vivo tissues 24.  Overall, 3D cultures 
recapitulate in vivo cell-cell and cell-matrix interactions more successfully than 2D plastic 
substrate cultures.  Thus, 3D culture models allow for the emergence of more physiologically 
relevant cell phenotypes.  
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Tissue specific organoid models for translational medicine 
 
Stem and multipotent progenitor cell-derived organoids exist for many tissues, with an 
ever-increasing number derived from both human and animal tissues.  Of these, liver, lung, and 
gastrointestinal epithelial organoid models are of particular interest for translational medicine.  
This is because failures to predict toxicity and/or efficacy within these organs are a prominent 
cause of late-stage drug failures 25-28. 
   
Liver organoid models 
 
 The demand for physiologically relevant models of human liver is high given that 20% 
of drugs fail during Phase III clinical trials due to unforeseen hepatotoxic side effects 29.  
Unfortunately, traditional 2D hepatocyte cultures respond abnormally to a wide variety of 
stimuli and are therefore often unsuitable for accurately determining drug safety profiles 30.   
 
 There are currently two main approaches for generating physiologically relevant liver 
organoids: sandwich cultures and self-assembling spheroids 28, 31. In sandwich culture models, 
patient-derived hepatocyte progenitor cells are seeded between layers of collagen or Matrigel in 
order to replicate in vivo liver morphology and maintain epithelial hepatocyte polarity 28. In 
contrast, self-assembling spheroids are formed when hepatocyte progenitor cells are cultured 
alongside stromal cells in a collagen sponge 31, 32.  Spheroids such as these more closely 
resemble in vivo hepatocyte physiology with cells forming better tight junctions, cell polarity, 
protein expression and metabolic activity.  These characteristics increase hepatic organoid 
sensitivity to pharmacotoxic compounds relative to conventional 2D hepatocyte cultures 33.  In 
addition to toxicity assays, preclinical targets and techniques that could be investigated in a 
high throughput manner using hepatic organoids include phase 1 and phase 2 metabolic 
function, ex vivo bile production, and hepatic coagulation cascade protein expression.   
 
 Unfortunately, both hepatocyte sandwich culture and self-assembling spheroid model 
systems currently exhibit only limited in vitro growth and longevity.  This is most likely 
because identified populations of human hepatocyte progenitor cells are not sufficient for long-
term organoid culture as was initially found during attempts to generate intestinal organoids 34.  
As such it may be necessary to identify and isolate different cell populations from human liver 
that are capable of sustaining long-term organoid viability.  Currently, the identity of long-term 
human liver stem and progenitor cells remains controversial 35.     
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Lung organoid models 
 
 Respiratory diseases account for nearly 1 in 5 deaths worldwide and lung cancer 
survival rates remain poor despite numerous therapeutic advances during the past 30 years 36. 
These figures highlight the need for new, physiologically relevant models for translational lung 
research.  In recent years, Matrigel-based organoid models have been established that enable 
proximal airway stem or progenitor cells to differentiate in a physiologically relevant manner 
13, 37-39
. In humans organoids are basal cell-derived and demonstrate intrinsic self-renewal 38, 
multipotent secretory, basal and ciliated cell differentiation 38, and in rare cases airway-like 
branching 15. Although it remains unclear whether all basal cells represent stem cells or instead 
multipotent committed progenitor cells40, mcroarray analysis nonetheless shows that 
differentiated human basal epithelial cell cultures share a similar transcriptional profile to in 
vivo airways 41.  Further work is now required to improve the efficiency of airway organoid 
formation and better characterize the cell types responsible for 3D organoid differentiation.   
 
 Although airway organoid assays remain in their infancy, it is becoming realistic to 
imagine the generation of a range of organoid models derived from multiple healthy and 
diseased patient biopsies. These could be selected to represent a range of respiratory diseases 
and to account for interindividual population variability. These properties suggest that airway 
organoid models will be useful in a wide range of translational research including toxicity, drug 
efficacy and mucociliary clearance studies. Indeed Balharry and colleagues report that airway 
organoid cultures and in vivo airways exhibit similar stress responses following toxin exposure 
42
.Preclinical high throughput screening of airway organoids will likely include assays for 
airway mucous production and secretion, ciliated cell differentiation and function, and airway 
pathogen resistance.   
 
Gastrointestinal organoid models 
 
 The need for clinically relevant models of the gastrointestinal (GI) system is high, 
particularly given the worldwide prevalence of human intestinal disease. Historically, 
preclinical GI translational medical research has relied entirely on animal models and cancer 
cell cultures that are of limited relevance to human physiology 34, 43. However, in 2009 the first 
long-term organoid models of the small intestine were established using 3D Matrigel 9 systems. 
GI organoid models have since been adapted to support derivation of normal stomach 44, 
intestine and colonic organoids 34.  The multipotent differentiation capacity of these models 
suggests that they will provide a valuable resource for translational medicine.  They are also 
likely to benefit investigations of the role commensal bacteria populations play in maintaining 
intestinal health 43.  
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 In addition to deriving organoid models from healthy patient tissues, the Clevers group 
have also established epithelial organoid models from human colorectal cancers and 
metaplastic Barrett’s oesophagus epithelia 34. These disease-specific organoid models now 
provide the potential for testing therapeutic target efficacy as well as compound toxicity in a 
preclinical, high-throughput setting.  Specific preclinical targets and high throughput assays 
could include screening for cellular proliferation and monitoring intestinal epithelial cell 
differentiation.  Overall, recent progress suggests that human stem cell-derived organoid 
models will be an invaluable tool for improving the efficiency of GI translational medicine. 
 
Other epithelial organoid models 
 
 Clinically, the pancreas is an important translational medicine target given that type I 
and type II diabetes now affects 350 million people worldwide.  Separately, the development of 
kidney organoids is an additional high-priority target as the prevalence of renal disease has 
increased significantly in recent years.   Although the identity of human kidney stem cells 
amenable to organoid derivation remains elusive 45, the recent description of a multipotent stem 
cell population in adult human pancreas raises the possibility of developing biologically 
relevant pancreatic organoid models 46.  
 
Pluripotent cell-derived epithelial organoids 
 
In recent years the capacity to generate organoids from pluripotent embryonic stem (ES) 
and induced pluripotent stem (iPS) cells has been reported, generally using approaches that 
mimic normal developmental processes through the step-wise application of various signaling 
molecules 47. Using these techniques, intestinal organoids have been derived from both ES and 
iPS cells 48.  More recently, protocols to direct human pluripotent cells towards airway 
differentiation have also emerged 49, 50.   Despite these advances, it is not yet known how well 
ES and iPS-derived epithelial organoids will replicate true in vivo differentiation. This is 
because the long-term influence of epigenetic changes introduced during iPS and ES cell 
derivation and differentiation remains incompletely understood 51.  It therefore remains to be 
determined whether ES and iPS-derived organoids will be useful for preclinical translational 
medicine.  
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Figure 2.   A paradigm for high content, high throughput epithelial organoid screening in 
translational medicine.  Stem cells or multipotent progenitor cells derived from human biopsies 
will be expanded in vitro and used to derived patient-specific organoids.  These will be 
amenable to high throughput, high content automated compound screening given their 
resemblance to normal in vivo tissues.   
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A paradigm for organoid models in translational medicine 
 
Improving translational medicine from fundamental biomedical discovery to 
pharmaceutical product requires models capable of producing high-quality, high content and 
high-throughput data.  Here, we propose a paradigm in which human stem cell-derived 
organoid models may be used in a high-throughput and high content epithelial translational 
medicine pipeline (Figure 2). We propose that tissue samples could be obtained using 
minimally invasive biopsy procedures from healthy and diseased patients.  Stem or long term 
progenitor cells present in patient biopsies could then be isolated based on unique cell surface 
proteins, rapidly expanded in number following a brief 2D culture, and seeded in organoid 
forming assays as described above.  The validity of this approach was recently demonstrated 
using human intestinal SCs derived from patient biopsies34.  Multiwell plate-based organoid 
assays would then be channeled into compound toxicity and efficacy screening systems such as 
gene expression microarray, protein mass-spectrometry, and multiplex ELISA platforms.  High 
throughput and high content analysis would be achieved using automated cell manipulation and 
readout systems.    
 
 
Summary and future directions 
 
 In order for high-throughput, high content organoid assays to become a reality several 
outstanding questions remain to be addressed.  Existing organ-specific 3D cell culture models 
must be optimized to allow consistent, efficient and reproducible organoid formation.  This will 
involve reducing heterogeneity within the organoid-initiating cell population through better 
characterization of initiating cell types and improving tissue-specific organoid growth 
conditions.  It will also be necessary to optimize organoid forming assays to better replicate in 
vivo organ physiology at a functional, cellular, and molecular level.  Finally, it is of critical 
importance that biologically relevant preclinical targets are identified to facilitate organoid-
based pharmacological lead validation.   
 
 Overall, we feel that our paradigm for stem cell-derived organoid models in epithelial 
translational medicine has the potential to improve preclinical testing and pharmacological 
compound validation.  We believe that 3D organoid modeling will allow one to assess both 
compound efficacy and safety in a high throughput and high content manner while additionally 
addressing interindividual human population variability.  Thus, our paradigm should provide 
improved target identification, lead validation, and lead optimization in a single cost-effective, 
high content and high-throughput assay. In future studies, we envisage expansion of this 
paradigm beyond simple epithelial organoids and towards development of novel ectodermal 
and mesodermal-derived organoid models relevant for human translational medicine.   
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